Lonza's API manufacturing facility expansion in China enters commercial operation

Swiss contract development and manufacturing organization (CDMO) Lonza today announced the start of new mid-scale manufacturing assets at its active pharmaceutical ingredients (API) manufacturing center in Nansha, China.

Commercial mid-scale operations are now underway at the expanded manufacturing facility, which was part of a 20 million Swiss franc ($18.8 million) investment that was announced in July last year, said Lonza, a company that is notching up annual revenues of some 5.4 billion francs.

The expansion includes six 1,000L reactors, four 1,500L reactors, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. Lonza says the investments allows itto provide customers with a smoother transition from small to large-scale manufacturing while maintaining global quality and regulatory standards.